SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13G
                                (RULE 13d - 102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d)
               AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)

                               (Amendment No.___)*

                             ZIOPHARM Oncology, Inc.
                                (Name of Issuer)

                                  Common Stock
                         (Title of Class of Securities)

                                    27784W203
                                 (CUSIP Number)

                               September 13, 2005
             (Date of Event which Requires Filing of this Statement)

Check the  appropriate box to designate the rule pursuant to which this Schedule
is filed:

[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)

*The  remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for  any  subsequent   amendment   containing   information  which  would  alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 ("Act") or otherwise  subject to the liabilities of that section of the Act
but  shall be  subject  to all other  provisions  of the Act  (however,  see the
Notes).

                       (Continued on the Following Pages)



1.       NAMES OF REPORTING PERSONS
         I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

                  Paloma International L.P.

2.       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

         (a)      [x]
         (b)      [ ]

3.       SEC USE ONLY

4.       CITIZENSHIP OR PLACE OF ORGANIZATION

                  Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

5.       SOLE VOTING POWER

                  1,214,456

6.       SHARED VOTING POWER

                  0

7.       SOLE DISPOSITIVE POWER

                  1,214,456

8.       SHARED DISPOSITIVE POWER

                  0

9.       AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                  1,214,456

10.      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
         EXCLUDES CERTAIN SHARES*   [ ]

11.      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

                  17.0%

12.      TYPE OF REPORTING PERSON*

                  PN

                      *SEE INSTRUCTIONS BEFORE FILLING OUT!



1.       NAMES OF REPORTING PERSONS
         I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

                  S. Donald Sussman

2.       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

         (a)      [x]
         (b)      [ ]

3.       SEC USE ONLY

4.       CITIZENSHIP OR PLACE OF ORGANIZATION

                  United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.       SOLE VOTING POWER

                  1,214,456

6.       SHARED VOTING POWER

                  0

7.       SOLE DISPOSITIVE POWER

                  1,214,456

8.       SHARED DISPOSITIVE POWER

                  0

9.       AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                  1,214,456

10.      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
         EXCLUDES CERTAIN SHARES*   [ ]

11.      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

                  17.0%

12.      TYPE OF REPORTING PERSON*

                  IN

                      *SEE INSTRUCTIONS BEFORE FILLING OUT!



ITEM 1(a).        Name of Issuer:

     ZIOPHARM Oncology, Inc. (the "Issuer").

Item 1(b).        Address of Issuer's Principal Executive Offices:

     1180 Avenue of the Americas, 19th Floor
     New York, New York 10036

Item 2(a).        Name of Persons Filing:

     The names of the persons filing this statement on Schedule 13G are:  Paloma
International  L.P., a Delaware  limited  partnership  ("Paloma")  and S. Donald
Sussman (collectively, the "Reporting Persons").

Item 2(b).        Address of Principal Business Office or, if None, Residence:

     The principal business address for Paloma is Two American Lane,  Greenwich,
Connecticut  06836.  The principal  business address for Mr. Sussman is 6100 Red
Hook Quarter,  18B,  Suites C, 1-6, St.  Thomas,  United  States Virgin  Islands
00802.

Item 2(c).        Citizenship:

     Paloma is a Delaware limited  partnership.  Mr. Sussman is a citizen of the
United States.

Item 2(d).        Title of Class of Securities

     Common Stock, par value $.001 (the "Common Stock").

Item 2(e).        CUSIP Number:  27784W203

Item 3.           If This Statement is Filed Pursuant to Rule 13d-1(b),
                  or 13d-2(b) or (c), Check Whether the Person Filing is a:

     (a)  [ ] Broker or dealer registered under Section 15 of the Exchange Act.

     (b)  [ ] Bank as defined in Section 3(a)(6) of the Exchange Act.

     (c)  [ ] Insurance company defined in Section 3(a)(19) of the Exchange Act.

     (d)  [ ] Investment company  registered  under Section 8 of the  Investment
              Company Act.

     (e)  [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

     (f)  [ ] An employee benefit plan or endowment fund in accordance with Rule
              13d-1(b)(1)(ii)(F).

     (g)  [ ] A parent holding company or control person in accordance with Rule
              13d-1(b)(1)(ii)(G).

     (h)  [ ] A savings association  as defined in Section  3(b) of the  Federal
              Deposit Insurance Act.


     (i)  [ ] A church plan that is excluded from the definition of an
              investment company under Section 3(c)(14) of the Investment
              Company Act;

     (j)  [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Rule 13d-1(c), check this box [x]

Item 4.   Ownership.

     Provide  the  following  information  regarding  the  aggregate  number and
percentage of the class of securities of the issuer identified in Item 1.

     (a)  Amount beneficially owned:

          The Reporting  Persons  beneficially  own  1,214,456  shares of Common
          Stock.

     (b)  Percent of class:

          The Reporting Persons have beneficial ownership of 1,214,456 shares of
          Common Stock  constituting  17.0% of all of the outstanding  shares of
          Common Stock.

     (c)  Number of shares as to which such person has:

          (i)   Sole power to vote or to direct the vote

                Each of Paloma and S. Donald  Sussman has the sole power to vote
                or direct the vote of 1,214,456 shares of Common Stock.

          (ii)  Shared power to vote or to direct the vote

                Not applicable.

          (iii) Sole power to dispose or to direct the disposition of

                Each of  Paloma  and S. Donald  Sussman  has the  sole  power to
                dispose or direct the disposition of 1,214,456  shares of Common
                Stock.

          (iv)  Shared power to dispose or to direct the disposition of

          Not applicable.

Item 5.   Ownership of Five Percent or Less of a Class.

     If this  statement  is being  filed to report  the fact that as of the date
hereof the Reporting Persons have ceased to be the beneficial owner of more than
five percent of the class of securities, check the following [ ].

Item 6.   Ownership of More than Five Percent on Behalf of Another Person.

     Not applicable.



Item 7.   Identification and Classification of the Subsidiary Which Acquired the
          Security Being Reported on by the Parent Holding Company.

     Paloma holds its 1,214,456 shares of Common Stock that it beneficially owns
through its wholly-owned  subsidiary,  Mibars LLC, a Delaware limited  liability
company.

Item 8.   Identification and Classification of Members of the Group.

     See Exhibit B attached hereto.

Item 9.   Notice of Dissolution of Group.

     Not applicable.

Item 10.  Certification.

     By  signing  below  the  undersigned  certifies  that,  to the  best of its
knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing  or  influencing  the
control of the issuer of the  securities  and were not acquired and are not held
in connection with or as a participant in any transaction having that purpose or
effect.



                                   SIGNATURES

     After reasonable inquiry and to the best of its knowledge and belief,  each
of the undersigned  certifies that the information  with respect to it set forth
in this statement is true, complete, and correct.


Dated:  September 23, 2005

        PALOMA INTERNATIONAL L.P.
        By: Paloma GP LLC, general partner


            By: /s/ Michael J. Berner
                ---------------------
                    Michael J. Berner
                    Vice President


        /s/ S. Donald Sussman
        ---------------------
            S. Donald Sussman



                                    EXHIBIT A
                             JOINT FILING AGREEMENT

     The  undersigned  hereby  agree that the  statement  on  Schedule  13G with
respect to the Common Stock of ZIOPHARM Oncology,  Inc. dated September 23, 2005
is, and any further  amendments  thereto signed by each of the undersigned shall
be,  filed on behalf of each of the  undersigned  pursuant to and in  accordance
with the provisions of Rule 13d-1(k) under the Securities  Exchange Act of 1934,
as amended.


Dated:  September 23, 2005

        PALOMA INTERNATIONAL L.P.
        By: Paloma GP LLC, general partner


            By: /s/ Michael J. Berner
                ---------------------
                    Michael J. Berner
                    Vice President


        /s/ S. Donald Sussman
        ---------------------
            S. Donald Sussman



                                    EXHIBIT B
                     IDENTIFICATION OF MEMBERS OF THE GROUP



Paloma International L.P.
S. Donald Sussman